Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glenmark stops four as competition bites

Executive Summary

Glenmark has discontinued development of four in-licensed complex generic projects in the US, on the basis that the “overall business case for these assets has significantly weakened due to the intense competitive landscape”. The Indian firm will no longer work on in-licensed generics of Abraxane (protein-based paclitaxel), NuvaRing (etonogestrel/ethinylestradiol), Concerta (methylphenidate) and Suboxone (buprenorphine/naloxone) following the action. Intangible asset-impairment charges totalling Rs1.78 billion (US$25 million) linked to the decision were recorded in Glenmark’s financial second quarter.

You may also be interested in...

FDA Shuts The Door On Celgene’s Abraxane Petition

ANDA and 505(b)(2) sponsors have been handed a boost after the FDA denied almost entirely a citizen petition filed by Bristol Myers Squibb’s Celgene which called for additional tests for rivals to its Abraxane oncology agent.

Amneal Wins Race For US NuvaRing Rival

Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.

Glenmark Plans To Spin Out A US-Based ‘Innovation’ Business – And May Pull The Plug On Advair

Having amassed a significant pipeline of innovative assets, India’s Glenmark has made the choice to spin them off into a new company that will be housed in the US. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts